Cell Therapy FCR001 to Enter Phase 1/2a Trial for Diffuse Cutaneous SSc

Dinesh Khanna, MD, MSc to conduct a clinical trial that will test an investigational cell therapy designed to promote immune tolerance and minimize the risk of graft-versus-host disease.